KW-1070にかんする臨床的検討 (KW-1070(FORTIMICIN)<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
KW-1070, a new antibiotic aminoglycoside developed in Japan, was given to 2 patients with acute cystitis, 3 with acute pyelonephritis and 1 with pneumonia.<BR>The daily dosage was 400 mg. The duration of administration ranged from 7.5 days to 12.5 days.<BR>The efficacy rate was 100 percent.<BR>Thrombocytepenia was detected in 1 patient, and an elevation in both serum GOT level and serum GPT level was detected in 1 patient. However, these side effects were all reversible, and no other side effects were observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.